Melanotan-1 (afamelanotide) is a synthetic tridecapeptide analog of the endogenous hormone alpha-melanocyte-stimulating hormone (alpha-MSH), engineered for markedly greater potency and metabolic stability at the melanocortin-1 receptor (MC1R). First reported in 1980, it became a widely used research probe for melanocortin pharmacology and for UV-independent melanogenesis. This overview summarizes its chemical identity, its mechanism of action as described in the literature, and the peer-reviewed findings that characterize its pharmacology. It is presented strictly within a laboratory and research context.

Background & Discovery

Melanotan-1, known by its International Nonproprietary Name afamelanotide, is a synthetic analog of the endogenous tridecapeptide alpha-melanocyte-stimulating hormone (alpha-MSH), a proopiomelanocortin (POMC)-derived hormone that regulates cutaneous pigmentation. The molecule was first reported by Sawyer and colleagues in 1980, who set out to overcome the two principal limitations of native alpha-MSH as a research tool: its rapid enzymatic degradation and its short duration of action. By substituting norleucine for methionine at position 4 and the D-enantiomer of phenylalanine for L-phenylalanine at position 7, the investigators produced a superpotent, protease-resistant peptide. In their original characterization the analog was reported to be approximately 26-fold more potent than alpha-MSH in a frog-skin adenylate cyclase assay and to display markedly prolonged ("ultralong") biological activity, properties that made it an important probe for studying melanotropin receptors on normal and malignant melanocytes.

Because it drives melanogenesis through the melanocortin-1 receptor, Melanotan-1 became a central pharmacological tool for investigating how the eumelanin pathway can be pharmacologically upregulated independently of ultraviolet (UV) exposure. Research literature characterizes it as a "chemical" or "sunless" inducer of skin pigmentation, and much of the early human pharmacology work (in the 1990s and 2000s) examined whether MC1R-driven eumelanin synthesis could confer photoprotection. The pharmaceutical form, afamelanotide, was subsequently developed by Clinuvel Pharmaceuticals as a slow-release subcutaneous bioresorbable implant (SCENESSE) and studied in controlled trials, most prominently for the rare inherited photodermatosis erythropoietic protoporphyria (EPP).

It is important to distinguish the compound at the level of nomenclature. Melanotan-1 (afamelanotide) is a linear 13-amino-acid peptide and is the same molecule referred to as NDP-MSH or [Nle4-D-Phe7]-alpha-MSH in the biochemical literature. It should not be confused with Melanotan-II, a distinct, smaller cyclic heptapeptide with a different receptor selectivity profile. Within a research-supply context, Melanotan-1 is categorized as a melanocortin receptor agonist peptide intended strictly for laboratory and research use.

Chemical Identity

Structure & Physicochemical Properties

Melanotan-1 is a linear tridecapeptide with the empirical formula C78H111N21O19 and an average molecular weight of approximately 1646.9 g/mol (PubChem CID 16197727; CAS 75921-69-6). Its sequence, Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, incorporates four features relative to native alpha-MSH that govern its physicochemical behavior: N-terminal acetylation and C-terminal amidation cap the peptide termini, the Met-to-Nle substitution removes an oxidation-labile thioether side chain, and the L-to-D inversion at Phe7 imparts resistance to enzymatic cleavage. Collectively these modifications increase metabolic stability and prolong the effective half-life relative to the parent hormone, which is the property the original Sawyer report described as "ultralong" biological activity.

As a synthetic peptide, Melanotan-1 is typically supplied as a lyophilized (freeze-dried) white to off-white powder. Reference literature and supplier characterizations describe it as water-soluble and soluble in dilute aqueous buffers; the presence of multiple charged and polar residues (Glu, His, Arg, Lys, plus the free-base termini treatments) supports aqueous solubility, while the aromatic Tyr, His, Phe and Trp residues give it characteristic UV absorbance useful for analytical quantitation. As with most peptides bearing labile residues, published handling guidance emphasizes protection from repeated freeze-thaw cycles, elevated temperature, and prolonged exposure to light, all of which can promote aggregation, oxidation or deamidation.

Mechanism of Action — as described in the literature

Melanotan-1 acts as a high-affinity agonist of the melanocortin-1 receptor (MC1R), a Gs-protein-coupled receptor expressed on epidermal melanocytes. Native alpha-MSH is the principal physiological ligand of MC1R, and the Nle4/D-Phe7 substitutions preserve the message sequence (His-Phe-Arg-Trp) required for receptor activation while dramatically improving binding kinetics and metabolic stability. Published receptor-pharmacology characterizations report subnanomolar affinity at MC1R, with substantially lower (weaker) affinity at the related melanocortin receptors MC3R, MC4R and MC5R, giving the peptide a pigmentation-oriented but not fully MC1R-exclusive profile.

Upon binding MC1R, the peptide stabilizes the active receptor conformation and activates adenylate cyclase via Gs, raising intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB and upregulates microphthalmia-associated transcription factor (MITF), the master regulator of the melanocyte lineage. MITF in turn drives transcription of the key melanogenic enzymes tyrosinase, tyrosinase-related protein 1 (TYRP1) and dopachrome tautomerase (TYRP2/DCT). The net downstream effect reported in the literature is a shift of melanin synthesis toward eumelanin (the brown-black, more photostable pigment) rather than the red-yellow pheomelanin.

Because the pathway is engaged pharmacologically at the receptor level, this mechanism is described in the literature as UV-independent melanogenesis: pigment production is stimulated without the DNA-damaging ultraviolet signal that normally initiates the physiological tanning response. In human pharmacodynamic studies, this manifested as measurable increases in cutaneous melanin density and eumelanin content, together with a rise in the eumelanin-to-pheomelanin ratio. The resulting increase in epidermal eumelanin is the proposed basis for the photoprotective effects characterized in subsequent clinical research.

The photoprotective rationale extends beyond simple optical filtering. In fair-skinned human volunteers, researchers reported that MC1R activation was associated with reductions in UV-induced markers of DNA and cellular damage, including epidermal sunburn (apoptotic keratinocyte) cell counts and cyclobutane thymine dimer formation. Melanocortin signaling has additionally been described in the broader literature as modulating oxidative stress responses and inflammatory mediators, mechanisms invoked to explain benefits observed in photodermatoses that are not solely attributable to increased pigment.

In the specific setting of erythropoietic protoporphyria, where accumulated protoporphyrin IX generates reactive oxygen species and phototoxic pain on light exposure, the working model in the clinical literature is that afamelanotide-induced eumelanin increases dermal light absorption and, together with antioxidant/anti-inflammatory melanocortin effects, raises the threshold for phototoxic reactions. This is characterized as symptomatic photoprotection rather than correction of the underlying enzymatic defect of heme biosynthesis.

Key Published Findings

• Foundational receptor pharmacology. In the original synthesis and characterization, the [Nle4-D-Phe7]-alpha-MSH analog was reported to be approximately 26 times more potent than native alpha-MSH in a frog-skin adenylate cyclase assay and to show marked resistance to enzymatic degradation with prolonged (ultralong) biological activity, establishing it as a superpotent melanotropin research probe.[1]
• Human pharmacodynamics of eumelanin induction. In seven volunteers with skin types III-IV, subcutaneous administration of the peptide increased eumelanin content by roughly 49% in forehead skin and 98% in forearm skin one week after treatment, and raised the eumelanin-to-pheomelanin ratio (from about 51:1 to 86:1 in forearm tissue), demonstrating a shift toward photostable eumelanin.[2]
• Photoprotection and UV-damage markers. In a study of fair-skinned Caucasian volunteers receiving the peptide, epidermal sunburn cells were reduced by more than 50% in participants with low baseline minimal erythema dose, and cyclobutane thymine dimer formation in the epidermal basal layer was reduced by about 59%, alongside significant increases in melanin density.[3]
• Proof-of-concept in erythropoietic protoporphyria. In EPP patients treated with a subcutaneous afamelanotide implant, tolerance to natural sunlight was reported to increase up to 24-fold relative to pre-treatment, with minimal phototoxic symptoms after day 4 and significantly increased cutaneous melanin density.[4]
• Randomized controlled trial in EPP. In two multicenter randomized placebo-controlled trials, afamelanotide implants were associated with increased duration of pain-free sun/light exposure and improved quality-of-life scores in EPP patients, with an acceptable adverse-event profile over the observation period.[7]
• Repigmentation in vitiligo. In a randomized multicenter trial combining afamelanotide implants with narrowband UV-B phototherapy versus NB-UV-B alone, the combination group achieved greater repigmentation (approximately 49% versus 33% at day 168), with more pronounced and faster facial response in patients with darker skin phototypes (Fitzpatrick IV-VI).[8]
• Systemic photoprotection in solar urticaria. In patients with solar urticaria, an afamelanotide implant increased skin melanin density and produced a significant reduction in weal area across responding wavelengths from 300 to 600 nm at 60 days post-implant, with more than a twofold rise in the minimum urticarial dose threshold.[5]

Research Applications

• Investigated as a UV-independent inducer of cutaneous melanogenesis and eumelanin synthesis via MC1R activation in human and animal skin models
• Investigated in rodent and amphibian bioassays and cell-based systems as a superpotent, protease-resistant molecular probe of melanocortin-1 receptor pharmacology
• Studied as a systemic photoprotective agent in erythropoietic protoporphyria (EPP) and related protoporphyrias in controlled clinical research
• Examined in combination with narrowband UV-B phototherapy for repigmentation in nonsegmental vitiligo
• Investigated for symptom mitigation in photodermatoses including solar urticaria and polymorphous light eruption
• Used to study UV-induced DNA damage endpoints (thymine dimers) and epidermal sunburn-cell formation in fair-skinned human volunteers
• Employed in melanocyte and melanoma cell-biology research to probe tyrosinase activation, MITF signaling and eumelanin/pheomelanin switching
• Studied in melanocortin-receptor structure-activity and receptor-selectivity investigations across MC1R, MC3R, MC4R and MC5R

Related & Comparator Compounds

The most direct comparator is native alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous 13-residue POMC-derived ligand from which Melanotan-1 is engineered; the literature distinguishes the two by Melanotan-1’s Nle4/D-Phe7 substitutions, which confer subnanomolar MC1R affinity, protease resistance and prolonged action absent in the rapidly degraded parent hormone. Melanotan-1 is frequently confused with Melanotan-II, but the two are chemically distinct: Melanotan-II is a smaller cyclic heptapeptide with broader melanocortin-receptor activity (including notable MC3R/MC4R engagement), and its distinct pharmacology is reflected in different reported effects in the research literature. Afamelanotide is simply the International Nonproprietary Name and pharmaceutical (implant) form of the same Melanotan-1 molecule, not a separate compound. Other melanocortin-pathway research agents referenced as comparators include bremelanotide (PT-141), an MC4R-preferring analog studied in different physiological contexts, and setmelanotide, an MC4R-selective agonist used in metabolic/appetite research; both differ from Melanotan-1 in receptor selectivity and research application.

Handling, Reconstitution & Storage

In a research context, Melanotan-1 is typically supplied as a lyophilized powder and is described in reference and supplier documentation as stored desiccated at low temperature (commonly -20 C for extended storage) and protected from light. Published handling practice for such peptides is to reconstitute the lyophilate in an appropriate sterile aqueous solvent (for example bacteriostatic or sterile water, or a dilute buffer) to a defined stock concentration, with brief gentle mixing rather than vigorous agitation to limit foaming and aggregation. Reconstituted peptide solutions are generally described as less stable than the dry powder and are commonly kept refrigerated for short-term laboratory use, with aliquoting recommended to avoid repeated freeze-thaw cycles that can degrade peptide integrity. These points describe general laboratory material-handling practice only and are not instructions for administration to humans or animals.

Analytical & Quality Considerations

Analytical characterization of Melanotan-1 as a research peptide typically relies on reversed-phase high-performance liquid chromatography (RP-HPLC) to assess chromatographic purity (often reported as greater than or equal to 95-98%) and on mass spectrometry (ESI-MS or MALDI-TOF) to confirm identity against the expected average mass of approximately 1646.9 Da and empirical formula C78H111N21O19. Because the molecule contains oxidation- and deamidation-susceptible chemistry despite the stabilizing Met-to-Nle substitution, orthogonal methods are valuable for detecting related-substance impurities, truncated or deletion sequences, and counterion/acetate and residual-solvent content; amino acid analysis or sequencing can corroborate the intended Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 sequence and the D-Phe7 stereochemistry. Independent third-party Certificates of Analysis matter because nominal identity does not guarantee actual purity, correct sequence, correct salt form, or accurate peptide content (net peptide versus gross mass), and confirmatory HPLC/MS on the specific lot is the standard way to verify that a supplied material corresponds to the intended compound for reproducible research.

Frequently Asked Research Questions

Q. Is Melanotan-1 the same thing as afamelanotide?
A. Yes. Afamelanotide is the International Nonproprietary Name (INN) for the same linear tridecapeptide known as Melanotan-1, [Nle4-D-Phe7]-alpha-MSH or NDP-MSH (CAS 75921-69-6). Afamelanotide most often refers to the developed pharmaceutical implant form of that identical molecule.

Q. How does Melanotan-1 differ from Melanotan-II?
A. They are chemically distinct peptides. Melanotan-1 is a linear 13-amino-acid alpha-MSH analog with high MC1R affinity, whereas Melanotan-II is a smaller cyclic heptapeptide with broader melanocortin-receptor activity. The research literature reports different receptor-selectivity profiles and different pharmacological effects for the two.

Q. What is the primary molecular target of Melanotan-1?
A. Published receptor-pharmacology data characterize it as a potent agonist of the melanocortin-1 receptor (MC1R) with subnanomolar affinity, and with weaker binding at MC3R, MC4R and MC5R. MC1R activation raises intracellular cAMP and upregulates MITF-driven eumelanin synthesis in melanocytes.

Q. Why was Melanotan-1 originally developed?
A. Sawyer and colleagues (1980) engineered the Nle4/D-Phe7 substitutions to create a protease-resistant, ultra-potent alpha-MSH analog for studying melanotropin receptors; it was reported to be roughly 26-fold more potent than native alpha-MSH in an adenylate cyclase assay with prolonged biological activity.

Q. What research areas is Melanotan-1 studied in?
A. Peer-reviewed literature examines it in UV-independent melanogenesis and MC1R pharmacology, and in clinical research on photoprotection in erythropoietic protoporphyria, repigmentation in vitiligo (with narrowband UV-B), and photodermatoses such as solar urticaria. It is also used as a melanocyte/melanoma cell-biology probe.

Q. How is chemical identity and purity of a research lot confirmed?
A. Standard practice combines RP-HPLC for purity with mass spectrometry to confirm the expected mass (approximately 1646.9 Da, C78H111N21O19), supported where possible by sequence/amino acid analysis. A lot-specific third-party Certificate of Analysis is the accepted way to verify identity, purity and net peptide content.

Peer-Reviewed References

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences of the United States of America. 1980. PubMed →
2. Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 2000. PubMed →
3. Barnetson RS, Ooi TK, Zhuang L, Halliday GM, Reid CM, Walker PC, Humphrey SM, Kleinig MJ. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. Journal of Investigative Dermatology. 2006. PubMed →
4. Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochemistry and Photobiology. 2009. PubMed →
5. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. British Journal of Dermatology. 2011. PubMed →
6. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. British Journal of Dermatology. 2015. PubMed →
7. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015. PubMed →
8. Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015. PubMed →
9. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology. 2016. PubMed →

For laboratory and research use only. Not for human or veterinary use, diagnosis, or treatment. This overview summarizes published scientific literature for informational and educational purposes and is not medical advice; no claims are made regarding safety or efficacy in humans.

← Back to the Research Library · View Melanotan-1 → · COA & Testing